The EC Approves Sanofi’s Sarclisa + standard-of-care VRd to Treat Newly Diagnosed Multiple Myeloma (NDMM)
Shots:
- The EC has approved Sarclisa with SoC VRd (bortezomib, lenalidomide, & dexamethasone) to treat ASCT-ineligible NDMM patients, following the CHMP’s positive opinion. Regulatory findings are under review in Japan & China
- Approval was based on a P-III (IMROZ) study assessing Sarclisa + VRd vs VRd, which showed improved PFS of 40% (1EP) with findings reported in Jun 2024
- Additionally, Sanofi is evaluating Sarclisa in various P-II & P-III studies for 6 potential indications across MM treatment, plus SC administration for Sarclisa is also under evaluation
Ref: Sanofi | Image: Sanofi
Related News:- Alloy Therapeutics Partners with Sanofi to Advance Innovative Therapeutics in the CNS Space
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
